Sirna Appoints Gregory Weaver as Chief Financial Officer
News Feb 10, 2006
Sirna Therapeutics, Inc. has announced the appointment of Gregory Weaver, CPA, MBA as the Company's Senior Vice President and Chief Financial Officer.
Mr. Weaver will direct and oversee Sirna's financial management, accounting activities and investor relations.
He will report to Howard W. Robin, President and Chief Executive Officer of Sirna. Mr. Weaver's appointment will be effective as of February 13, 2006.
"We are pleased to have Greg join the team at Sirna," stated Howard Robin. "He is a seasoned professional who has proven his ability to engage and work with the investment community."
"Greg brings an outstanding set of financial, transaction and strategic leadership skills to our team which we feel will be instrumental in building value for the organization both near and long term."
Mr. Weaver has extensive experience with both publicly traded and private companies, most recently serving as the Chief Financial Officer of Nastech Pharmaceutical Company and prior to that, the Chief Financial Officer at ILEX Oncology.
Throughout his career, Mr. Weaver has managed revenue and profit growth, manufacturing and R&D investments and has raised over $400 million in capital market transactions.
In addition, Mr. Weaver has either led or participated in mergers, acquisitions, in and out-licensing transactions valued at over $200 million.
"I am excited to join Sirna Therapeutics at a time when the company is looking to bring a second compound into the clinic," commented Mr. Weaver.
"The work being pioneered by Sirna presents an exciting opportunity for the biotech and investment communities."
"I look forward to working closely with the team at Sirna in continuing to build awareness of both their scientific breakthroughs and their industry leading efforts in developing RNAi-based therapeutics."
Mr. Weaver sits on the Board of Director's Executive Committee for the Washington Biotech and Biomedical Association and is currently a member of the Licensing Executive Society and the American Institute of CPA's.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.